Clinical Trial Update: Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants [Phase 2]

View source ↗

Summary

Phase 2 trial update assessing safety and immunogenicity of different dosing schedules for Takeda's tetravalent dengue vaccine candidate TDV in healthy adults, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue Fever

Drugs mentioned

• TDV (Takeda's tetravalent dengue vaccine candidate) (Tetravalent dengue vaccine candidate)

Snippet

Sponsor: Takeda | Conditions: Dengue Fever | Phase 2 | Status: COMPLETED | Results posted: 2020-02-24